How Has HCV Treatment Transformed the Potential for HCV Elimination?

Watch and listen as Jordan J. Feld, MD, MPH, and Natasha Martin, DPhil, discuss how dramatic changes in the HCV treatment landscape have enabled high cure rates to be safely achieved across a wide range of patient populations, including those previously excluded from HCV therapy because of previous or ongoing injection drug use. Expert faculty will also discuss how improved therapies have led to the concept of HCV treatment-as-prevention among high-risk populations as a critical strategy to reduce HCV incidence and prevalence in the United States.
Norah Terrault, MD, MPH
Program Director
Jordan J. Feld, MD, MPH
Natasha Martin, DPhil
Physicians: maximum of 0.5 AMA PRA Category 1 Credits
Registered Nurses: 0.4 Nursing contact hours
Pharmacists: 0.5 contact hours (0.05 CEUs)
Released: October 18, 2017 Expiration: October 17, 2018

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply clinical trial efficacy and safety data when devising strategies for treating HCV infection among populations at high risk for onward transmission, including persons who inject drugs, HIV-infected men who have sex with men, and incarcerated populations
  • Educate colleagues on the concept of HCV treatment-as-prevention among high-risk populations as a key strategy to reach HCV elimination targets

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Norah Terrault, MD, MPH

Professor of Medicine and Surgery
Director, Viral Hepatitis Center
Division of Gastroenterology
University of California, San Francisco
San Francisco, California

Norah Terrault, MD, MPH, has disclosed that she has received consulting fees from Gilead Sciences and Merck and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.

Faculty

Jordan J. Feld, MD, MPH

Associate Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Disease
Sandra Rotman Centre for Global Health
Toronto, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Theravance and funds for research support from AbbVie, Boehringer Ingelheim, Gilead Sciences, Janssen, Merck, and Santaris.
Natasha Martin, DPhil

Associate Professor
Division of Infectious Diseases and Global Public Health
University of California, San Diego
La Jolla, California

Natasha Martin, DPhil, has disclosed that she has received consulting fees and funds for research support from Gilead Sciences.

Staff

Jennifer Blanchette, PhD

Senior Scientific Director

Jennifer M. Blanchette, PhD, has no real or apparent conflicts of interest to report.
Edward King, MA

Executive Vice President

Edward King, MA, has no real or apparent conflicts of interest to report.
Megan K. Murphy, PhD

Associate Scientific Director

Megan K. Murphy, PhD, has no real or apparent conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This program is intended for physicians, registered nurses, pharmacists, and other healthcare providers involved in the screening, diagnosis, and treatment of patients infected with or at elevated risk of HCV.

Goal

The goal of this activity is to improve participants’ competence in implementing strategies to screen, diagnose, and cure diverse populations of individuals infected with HCV in the United States.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

This educational activity for 0.4 contact hour is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacist Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education (Universal Program Number – JA4008162-9999-18-220-H01-P).

Type of Activity: Knowledge

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 18, 2017, through October 17, 2018:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Audio from CCO faculty Dr. Nancy Reau on strategies to address gaps in viral hepatitis care: learn how to prevent HAV and HBV, how to screen for and treat HCV

Nancy Reau, MD Released: December 3, 2019

Downloadable slides on data from AALSD 2019 selected by expert faculty as relevant to care of patients with viral hepatitis or NAFLD/NASH, as reported by Clinical Care Options.

Ira M. Jacobson, MD Nancy Reau, MD Released: December 2, 2019

Downloadable slides from CCO and Dr. Nancy Reau on addressing gaps in viral hepatitis care: expert tips on managing HAV, HBV, HCV and on new AASLD guidance

Nancy Reau, MD Released: November 25, 2019

Clinical Care Options’ (CCO) expert audio analysis of new viral hepatitis data from AASLD 2019, provided by Norah Terrault, MD, MPH

Norah Terrault Headshot Norah Terrault, MD, MPH Released: November 22, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?